Tirbanubulin (Klisiry®) in the Treatment of Basal Cell Carcinoma

Summary

his is a Phase 2, Single-Arm, Open-Label, Single Center, to Assess Efficacy and Safety of Tirbanibulin Ointment 1% in Adult Subjects with superficial basal cell carcinoma (sBCC) not arising on the face or scalp

Timeline

Start

2024-02-16

Primary completion

2027-12-16

Completion

2027-12-16

Drugs

Indications